<DOC>
	<DOCNO>NCT01687387</DOCNO>
	<brief_summary>Double-Blind Placebo-Controlled Randomized Phase 2 Study evaluate efficacy lirilumab ( IPH2102/BMS-986015 ) Maintenance Treatment administer elderly patient Acute Myeloid Leukemia ( AML ) first complete remission</brief_summary>
	<brief_title>Efficacy Study Anti-KIR Monoclonal Antibody Maintenance Treatment Acute Myeloid Leukemia ( EFFIKIR )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . Primary secondary Acute Myeloid Leukemia ( AML , define accord WHO 2008 criterion ) , first CR/CRi ( accord revise recommendation International Working Group Diagnosis , Standardization Response Criteria , Treatment Outcomes , Reporting Standards Therapeutic Trials Acute Myeloid Leukemia J Clin Oncol . 2003 Dec 15 ; 21 ( 24 ) :46429 see appendix 19.3 ) follow induction chemotherapy receive 1 2 consolidation cycle . Induction chemotherapy perform within 6 month randomization . Consolidation cycle define chemotherapy administer within 3 month follow CR include aracytine irrespective administer dose ( ) . A minimum one maximum 2 cycle administer enrollment 2 . Patients eligible allogeneic hematopoietic cell transplantation 3 . Age 60 80 4 . ECOG Performance status 0 1 5 . Clinical laboratory value screen Calculated creatinine clearance ( accord MDRD ) &gt; 60 ml/min/1.73 m2 Platelet &gt; 75 x 109/l Hemoglobin ≥ 10 g/dl support unsupported transfusion ANC &gt; 1 x 109/l Total Bilirubin level ≤ 1.5 ULN ALT AST ≤ 3 ULN 6 . Recovery acute toxicity previous antitumor therapy 7 . Male patient accept able use contraception method recognize highly effective . 8 . Signed informed consent prior protocol specific procedure . 1 . Acute Promyelocytic Leukemia ( 15 ; 17 ) , molecular equivalent ( PMLRARA ) 2 . Favorable risk AML corresponding define ( 8 ; 21 ) inv ( 16 ) ( 16 ; 16 ) molecular equivalent ( AMLETO CBFBMYH11 ) 3 . Last consolidation complete 3 month prior first dose 4 . Concomitant treatment chemotherapy , immunotherapy systemic corticosteroid 5 . Within 28 day prior first dosing : chemotherapy systemic corticosteroid treatment 6 . History allogeneic hematopoietic cell transplantation solid organ transplantation 7 . History high dose chemotherapy autologous hematopoietic transplantation perform treatment AML 8 . Use investigational agent within 2 month prior first dose 9 . Use growth factor ( G GMCSF EPO ) within 28 day prior first dose 10 . Any irradiation within last 3 month except analgesic intent 11 . Intermittent continuous renal replacement therapy 12 . Abnormal cardiac status follow Ejection fraction ( measure ultrasound radionuclide image ) &lt; 50 % Myocardial infarction within previous 6 month QTc ≥ 480 m ( Bazett 's ) . 13 . Current active infectious disease positive serology HIV , and/or HCV detectable viremia and/ HBV positive Hbs Antigen and/or negative anti Hbs Antibody 14 . Autoimmune disease : Which currently previously require systemic immunosuppressive immunomodulatory therapy ( include corticosteroid administer systemic route ) And/or substantial probability cause irreversible injury tissue And/or recent unstable substantial risk progress cause severe complication . 15 . Serious concurrent uncontrolled medical disorder 16 . History another malignancy ( apart myelodysplastic syndrome , basal cell carcinoma skin , situ cervix carcinoma ) except free disease ≥ 3 year 17 . Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>